MMP-9: Biomarker for abdominal aneurysm

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Prior studies have shown the correlation between MMP-9 concentration levels with AAA raising the probability of its usage as a biomarker in AAA disease. However, results of previous studies have been conflicting. The purpose of this study is to identify the correlation between MMP-9 concentration levels with AAA disease and further define the utility as a biomarker for our center population. Materials and Methods: This is prospective controlled trial. Peripheral venous blood sample is obtained from 20 patients with AAA and 36 normal control subjects. MMP-9 concentration levels were determined by an enzyme-linked immunosorbent assay and compared with subjects abdominal ultrasonography or computed tomography of abdomen. Results: Mean (±SE) MMP-9 was 23.94 ± 0.60 ng/mL in normal control subjects and 21.39 ± 1.03 ng/mL in patients with AAAs (p ≤0.05 versus normal control subjects). MMP-9 correlate significantly with AAA (p=0.004). There was no correlation of MMP-9 levels with age, gender, or other risk factors. The cutoff point is 12.54 for aorta size <3.0cm. The sensitivity and specificity of MMP-9 were 60% and 64% respectively. Conclusions: MMP-9 levels correlate significantly with AAA with a cutoff point of 12.54. However, the utility of MMP-9 as a diagnostic test is limited due to low sensitivity and specificity. An elevated MMP-9 has limited use to predict the presence of AAA (positive predictive value: 60%) and a normal MMP-9 level was insufficient to determine the absence of AAA (negative predictive value: 36.1%).

Original languageEnglish
JournalClinica Terapeutica
Volume164
Issue number6 SUPPL
DOIs
Publication statusPublished - 2014

Fingerprint

Matrix Metalloproteinases
Aneurysm
Biomarkers
Sensitivity and Specificity
Routine Diagnostic Tests
Abdomen
Aorta
Ultrasonography
Enzyme-Linked Immunosorbent Assay
Tomography

Keywords

  • abdominal aortic aneurysm
  • Biomarker
  • MMP-9

ASJC Scopus subject areas

  • Medicine(all)

Cite this

MMP-9 : Biomarker for abdominal aneurysm. / Bin Affirul, Affirul Chairil; Md Idris, Mohamad Azim; Haruna Rashid, Hanafiah; Kamaruddin, Nor Azmi; Zakaria, Rozman.

In: Clinica Terapeutica, Vol. 164, No. 6 SUPPL, 2014.

Research output: Contribution to journalArticle

@article{d3c58b0a59e8474aaa359414db0ffd3d,
title = "MMP-9: Biomarker for abdominal aneurysm",
abstract = "Prior studies have shown the correlation between MMP-9 concentration levels with AAA raising the probability of its usage as a biomarker in AAA disease. However, results of previous studies have been conflicting. The purpose of this study is to identify the correlation between MMP-9 concentration levels with AAA disease and further define the utility as a biomarker for our center population. Materials and Methods: This is prospective controlled trial. Peripheral venous blood sample is obtained from 20 patients with AAA and 36 normal control subjects. MMP-9 concentration levels were determined by an enzyme-linked immunosorbent assay and compared with subjects abdominal ultrasonography or computed tomography of abdomen. Results: Mean (±SE) MMP-9 was 23.94 ± 0.60 ng/mL in normal control subjects and 21.39 ± 1.03 ng/mL in patients with AAAs (p ≤0.05 versus normal control subjects). MMP-9 correlate significantly with AAA (p=0.004). There was no correlation of MMP-9 levels with age, gender, or other risk factors. The cutoff point is 12.54 for aorta size <3.0cm. The sensitivity and specificity of MMP-9 were 60{\%} and 64{\%} respectively. Conclusions: MMP-9 levels correlate significantly with AAA with a cutoff point of 12.54. However, the utility of MMP-9 as a diagnostic test is limited due to low sensitivity and specificity. An elevated MMP-9 has limited use to predict the presence of AAA (positive predictive value: 60{\%}) and a normal MMP-9 level was insufficient to determine the absence of AAA (negative predictive value: 36.1{\%}).",
keywords = "abdominal aortic aneurysm, Biomarker, MMP-9",
author = "{Bin Affirul}, {Affirul Chairil} and {Md Idris}, {Mohamad Azim} and {Haruna Rashid}, Hanafiah and Kamaruddin, {Nor Azmi} and Rozman Zakaria",
year = "2014",
doi = "10.7417/CT.2013.1640",
language = "English",
volume = "164",
journal = "Clinica Terapeutica",
issn = "0009-9074",
publisher = "Societa Editrice Universo",
number = "6 SUPPL",

}

TY - JOUR

T1 - MMP-9

T2 - Biomarker for abdominal aneurysm

AU - Bin Affirul, Affirul Chairil

AU - Md Idris, Mohamad Azim

AU - Haruna Rashid, Hanafiah

AU - Kamaruddin, Nor Azmi

AU - Zakaria, Rozman

PY - 2014

Y1 - 2014

N2 - Prior studies have shown the correlation between MMP-9 concentration levels with AAA raising the probability of its usage as a biomarker in AAA disease. However, results of previous studies have been conflicting. The purpose of this study is to identify the correlation between MMP-9 concentration levels with AAA disease and further define the utility as a biomarker for our center population. Materials and Methods: This is prospective controlled trial. Peripheral venous blood sample is obtained from 20 patients with AAA and 36 normal control subjects. MMP-9 concentration levels were determined by an enzyme-linked immunosorbent assay and compared with subjects abdominal ultrasonography or computed tomography of abdomen. Results: Mean (±SE) MMP-9 was 23.94 ± 0.60 ng/mL in normal control subjects and 21.39 ± 1.03 ng/mL in patients with AAAs (p ≤0.05 versus normal control subjects). MMP-9 correlate significantly with AAA (p=0.004). There was no correlation of MMP-9 levels with age, gender, or other risk factors. The cutoff point is 12.54 for aorta size <3.0cm. The sensitivity and specificity of MMP-9 were 60% and 64% respectively. Conclusions: MMP-9 levels correlate significantly with AAA with a cutoff point of 12.54. However, the utility of MMP-9 as a diagnostic test is limited due to low sensitivity and specificity. An elevated MMP-9 has limited use to predict the presence of AAA (positive predictive value: 60%) and a normal MMP-9 level was insufficient to determine the absence of AAA (negative predictive value: 36.1%).

AB - Prior studies have shown the correlation between MMP-9 concentration levels with AAA raising the probability of its usage as a biomarker in AAA disease. However, results of previous studies have been conflicting. The purpose of this study is to identify the correlation between MMP-9 concentration levels with AAA disease and further define the utility as a biomarker for our center population. Materials and Methods: This is prospective controlled trial. Peripheral venous blood sample is obtained from 20 patients with AAA and 36 normal control subjects. MMP-9 concentration levels were determined by an enzyme-linked immunosorbent assay and compared with subjects abdominal ultrasonography or computed tomography of abdomen. Results: Mean (±SE) MMP-9 was 23.94 ± 0.60 ng/mL in normal control subjects and 21.39 ± 1.03 ng/mL in patients with AAAs (p ≤0.05 versus normal control subjects). MMP-9 correlate significantly with AAA (p=0.004). There was no correlation of MMP-9 levels with age, gender, or other risk factors. The cutoff point is 12.54 for aorta size <3.0cm. The sensitivity and specificity of MMP-9 were 60% and 64% respectively. Conclusions: MMP-9 levels correlate significantly with AAA with a cutoff point of 12.54. However, the utility of MMP-9 as a diagnostic test is limited due to low sensitivity and specificity. An elevated MMP-9 has limited use to predict the presence of AAA (positive predictive value: 60%) and a normal MMP-9 level was insufficient to determine the absence of AAA (negative predictive value: 36.1%).

KW - abdominal aortic aneurysm

KW - Biomarker

KW - MMP-9

UR - http://www.scopus.com/inward/record.url?scp=84896271978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896271978&partnerID=8YFLogxK

U2 - 10.7417/CT.2013.1640

DO - 10.7417/CT.2013.1640

M3 - Article

C2 - 24424226

AN - SCOPUS:84896271978

VL - 164

JO - Clinica Terapeutica

JF - Clinica Terapeutica

SN - 0009-9074

IS - 6 SUPPL

ER -